Analytical Evidence Report

HPLC-DAD results for the submitted Tirzepatide sample

REPORT NUMBER
DAYL-TIRZ-30-102626

GENERATED
November 27, 2026

Tirzepatide

Results and chromatograms

Sample 6026_0371 | Client report DAYL-TIRZ-30-102626

Lot # TNPS-TIRZ30-001 | Client: TrueNorth Peptide Supply

Laboratory Analysis: LAB-CA-01

VIAL PHOTOGRAPH


SAMPLE INFORMATION	
Label claim:	**30 mg**
Received:	**Oct 30, 2026**
Status:	**Data complete**
Submitted as:	**Tirzepatide**

ANALYSIS	
Purity at:	**214 nm**
Amount at:	**214 nm**
Run length:	**12.00 min**

RESULTS AT A GLANCE

PROJECTED AMOUNT	HPLC PURITY	CONTENT VS. LABEL	IDENTITY (LC-MS)
34.63 mg	**99.96%**	**115.4%**	**Confirmed**
BASED ON SAMPLE PREPARATION	214 NM AREA PERCENT	34.63 MG OF 30 MG CLAIMED	4+, 5+, 6+ AT 4.91 MIN

CHROMATOGRAM - 214 NM

Native 214 nm full-run detector readings



IDENTITY BY LC-MS

Triple quadrupole LC-MS, m/z 100-1400, +. Left: extracted ions; right: spectrum, 4.87-4.95 min





Compound	Ion	Expected m/z	Observed m/z	Mass from ion (Da)	Deviation	Apex (min)	Signal / noise	vs blank
● Tirzepatide	4+ [M+4H]	1204.37	1204.20	4,812.8	-0.014%	4.90	147,562	4,031x
● Tirzepatide	5+ [M+5H]	963.70	963.61	4,813.0	-0.009%	4.91	27,277	681x
● Tirzepatide	6+ [M+6H]	803.25	802.84	4,811.0	-0.051%	4.92	304	11x

BASIS OF THE RESULTS	
Purity:	**214 nm area percent, blank-corrected; main peak 8.975 min; 1 peak counted above the 0.594% reporting limit; 1 injection(s)**
Amount:	**Quantified against a certified reference standard by external calibration.**
Identity:	**Conforms**
Identity (LC-MS):	**Co-eluting charge states, mass within 0.1%, none in the blank**

LC-MS identity: confirmed at the intact mass (Expected (M+4H)4+, (M+5H)5+, (M+6H)6+ m/z peaks are observed together at 4.91 min and are absent from the blank; measured mass 4812.8 Da against 4813.5 Da expected (-0.014%)).

Results apply solely to the submitted sample as received; no conclusion is drawn on safety, efficacy, or regulatory status.
Verify this certificate: scan the QR code or visit testides.com/reports/DAYL-TIRZ-30-102626.